Problems in China pharmaceutical compulsory licensing system and their solutions
	    		
		   		
		   			
		   		
	    	
    	 
    	10.3969/j.issn.1671-3982.2017.06.009
   		
        
        	
        		- VernacularTitle:我国药品强制许可制度存在的问题及对策
 
        	
        	
        	
        		- Author:
	        		
		        		
		        		
			        		Di GAO
			        		
			        		;
		        		
		        		
		        		
			        		Jingfan XIE
			        		
			        		;
		        		
		        		
		        		
			        		Juanjuan HAN
			        		
			        		;
		        		
		        		
		        		
			        		Huiting CHAI
			        		
			        		;
		        		
		        		
		        		
			        		Jinhui GU
			        		
			        		
		        		
		        		
		        		
		        		
		        		
			        		
			        		
		        		
	        		
        		 
        	
        	
        	
        	
        		- Keywords:
        			
	        			
	        				
	        				
			        		
				        		Patent law;
			        		
			        		
			        		
				        		Compulsory licensing;
			        		
			        		
			        		
				        		Public health
			        		
			        		
	        			
        			
        		
 
        	
            
            
            	- From:Chinese Journal of Medical Library and Information Science
	            		
	            		 2017;26(6):36-40
	            	
            	
 
            
            
            	- CountryChina
 
            
            
            	- Language:Chinese
 
            
            
            	- 
		        	Abstract:
			       	
			       		
				        
				        	The Doha Declaration has entrusted to the members of WHO the right to use the compulsory licensing for drug patents in the face of global public health crises.Although the basic compulsory licensing system for drug patents has been established in China, the efficiency of its implementation is low, the responsibility of its executive departments is unclear, the related rules are not fully understood by pharmaceutical enterprises, it is thus necessary to improve and perfect the relevant legal provisions and systems in order to effectively improve the accessibility of drugs.